ECT Clinical Trials

4 recruiting

ECT Trials at a Glance

5,489 actively recruiting trials for ect are listed on ClinicalTrialsFinder across 6 cities in 141 countries. The largest study group is Not Applicable with 2,006 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running ect studies include National Cancer Institute (NCI), Assistance Publique - Hôpitaux de Paris, and Fudan University.

Treatments under study

About ECT Clinical Trials

Looking for clinical trials for ECT? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ECT trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ECT clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 5,489 trials

Recruiting

Host Response to Infection and Treatment in Filarial Diseases

HelminthiasisFilariasisParasitic Infection+2 more
National Institute of Allergy and Infectious Diseases (NIAID)500 enrolled1 locationNCT00001230
Recruiting
Phase 2

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell CarcinomaResectable Pancreatic CarcinomaResectable Pancreatic Adenocarcinoma+4 more
National Cancer Institute (NCI)152 enrolled453 locationsNCT04858334
Recruiting

Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients

AnthraxBacillus Infections
National Institute of Allergy and Infectious Diseases (NIAID)200 enrolled1 locationNCT00050310
Recruiting
Phase 1

MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)

HIV Infection
Merck Sharp & Dohme LLC28 enrolled2 locationsNCT07042945
Recruiting
Phase 2Phase 3

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)189 enrolled244 locationsNCT05058651
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2

Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study

Weight GainHealthy VolunteerMetabolic Effects+1 more
National Institute of Allergy and Infectious Diseases (NIAID)120 enrolled1 locationNCT05652478
Recruiting

Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV

ImmunodeficienciesHIVInfectious Diseases
National Institute of Allergy and Infectious Diseases (NIAID)2,419 enrolled2 locationsNCT00001281
Recruiting

Diagnosis and Treatment of Leishmania Infections

LeishmaniasisSkin Diseases, ParasiticEuglenozoa Infections+1 more
National Institute of Allergy and Infectious Diseases (NIAID)289 enrolled1 locationNCT00344188
Recruiting

Modeling Host-Pathogen Interaction Using Lymphoid Organoids

Staphylococcal Infections
National Institute of Allergy and Infectious Diseases (NIAID)500 enrolled2 locationsNCT06479837
Recruiting
Phase 1

A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

Congenital Cytomegalovirus Infection
National Institute of Allergy and Infectious Diseases (NIAID)12 enrolled10 locationsNCT06118515
Recruiting

Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies

Sample Collection
National Institute of Allergy and Infectious Diseases (NIAID)3,000 enrolled3 locationsNCT00067054
Recruiting
Phase 3

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Eyelid Squamous Cell Carcinoma+17 more
National Cancer Institute (NCI)420 enrolled206 locationsNCT06568172
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Not Applicable

Characterization of Nociception Phenotype in Individuals With Intellectual Disability

Intellectual Disability
National Institutes of Health Clinical Center (CC)215 enrolled1 locationNCT05473429
Recruiting
Not Applicable

The Vanguard Study: Testing a New Way to Screen for Cancer

Breast CarcinomaOvarian CarcinomaBladder Carcinoma+8 more
National Cancer Institute (NCI)24,000 enrolled37 locationsNCT06995898
Recruiting

Detection and Characterization of Host Defense Defects

Immune Defects
National Institute of Allergy and Infectious Diseases (NIAID)3,600 enrolled1 locationNCT00001355
Recruiting

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

PneumoniaInfectionsImmune System Diseases+2 more
National Institute of Allergy and Infectious Diseases (NIAID)600 enrolled1 locationNCT00006150
Recruiting
Phase 1

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Endometrial CancerColorectal CarcinomaNon-small Cell Lung Cancer+3 more
AstraZeneca108 enrolled18 locationsNCT06218914
Recruiting

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

Graft vs Host DiseaseGraft-versus-leukemiaGraft Rejection
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00106925